Welcome to our dedicated page for Dare Bioscience SEC filings (Ticker: DARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the cash-burn details behind Ovaprene® trials or spotting when Dare Bioscience insiders buy shares can take hours across multiple SEC PDFs. Biotech disclosures are dense, and Dare’s focus on women’s health brings extra layers of clinical data that investors cannot afford to miss. That complexity is the problem we solve.
Stock Titan’s AI reads every new submission the moment it hits EDGAR, then delivers plain-English answers. Need the Dare Bioscience quarterly earnings report 10-Q filing? Our summary highlights R&D spend, grant income and runway in seconds. Curious about Dare Bioscience insider trading Form 4 transactions? Real-time alerts flag each Dare Bioscience Form 4 insider transactions real-time, showing option grants tied to FDA milestones. For sudden study updates, the platform turns any Dare Bioscience 8-K material events explained into a concise brief you can read before the market reacts.
Every filing type is covered:
- 10-K – The Dare Bioscience annual report 10-K simplified spotlights pipeline status, partnership revenue and risk factors.
- 10-Q – Quarterly burn-rate trends with AI charts for quick Dare Bioscience earnings report filing analysis.
- 8-K – Trial results, FDA feedback, licensing deals distilled so you can act fast.
- Form 4 – Track Dare Bioscience executive stock transactions Form 4 to gauge insider confidence.
- DEF 14A – The Dare Bioscience proxy statement executive compensation section decodes pay structures vs. milestones.
Whether you’re a portfolio manager comparing cash runway or an analyst understanding Dare Bioscience SEC documents with AI, our platform ensures Dare Bioscience SEC filings explained simply are always one click away—complete, current and clear.
Dare Bioscience (NASDAQ:DARE) disclosed that Nasdaq's Hearings Panel has amended its decision regarding the company's delisting appeal and approved their modified compliance plan. The company must demonstrate compliance with either the $2.5 million stockholders' equity requirement or maintain a $35 million minimum market value by July 31, 2025, with a final deadline of August 12, 2025. Dare has been non-compliant with these requirements since August 2024. The Panel reserves the right to delist the stock before the deadline if the company fails to execute its plan satisfactorily.
FAQ
What is the current stock price of Dare Bioscience (DARE)?
What is the market cap of Dare Bioscience (DARE)?
What is the core focus of Dare Bioscience Inc?
How does the company generate revenue?
What are the key product candidates in Dare Bioscience’s portfolio?
How does Dare Bioscience ensure safety and efficacy in its clinical trials?
What makes Dare Bioscience unique in the biopharmaceutical industry?
What role do strategic collaborations play in the company’s development efforts?
How does the company address unmet needs in women’s health?
What is the company’s approach to regulatory interactions?
